文献速递炎症性肠病

维多珠单抗与乌司奴单抗暴露妊娠的母婴结局:PIANO登记研究结果

Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
PubMed 文献 · Am J Gastroenterol · 2023-10-05

该多中心前瞻性观察研究基于PIANO登记,纳入1669例单胎妊娠的炎症性肠病孕妇,其中维多珠单抗暴露66例、乌司奴单抗暴露47例。乌司奴单抗暴露组早产率0.0%,低于其他队列(P=0.03);两种药物均未增加流产、小于胎龄儿、低出生体重、新生儿重症监护、先天畸形或宫内生长受限风险。讨论建议妊娠期继续使用乌司奴单抗和维多珠单抗。

要点

  • 乌司奴单抗暴露组早产率0.0%,低于维多珠单抗(13.8%)、抗TNF(8.2%)等队列(P=0.03)。
  • 宫内暴露于维多珠单抗或乌司奴单抗未增加自发流产、小于胎龄儿、低出生体重、新生儿重症监护、先天畸形或宫内生长受限风险。
  • 讨论部分推荐妊娠期继续使用乌司奴单抗和维多珠单抗。

核心结论

  • 该分析提示妊娠期暴露于乌司奴单抗或维多珠单抗与抗TNF、免疫调节剂及联合治疗相比并发症未增加。
  • 未发现两种治疗增加胎盘事件信号。
  • 讨论推荐妊娠期继续使用乌司奴单抗和维多珠单抗。

研究设计与样本

  • 多中心前瞻性观察研究,纳入单胎妊娠且诊断为炎症性肠病的孕妇。
  • 在入组时、之后每个孕期、分娩时及出生后4、9、12个月发放问卷。
  • 采用双变量分析确定特定药物类别对结局的独立影响。
  • 暴露队列包括维多珠单抗、乌司奴单抗、抗TNF、免疫调节剂及抗TNF联合免疫调节剂,均与无暴露及生物制剂/免疫调节剂比较。
  • 共1669例完成妊娠,1610例活产;分娩时母亲平均年龄32.1岁(SD 4.6),维多珠单抗暴露66例,乌司奴单抗暴露47例。

主要发现

  • 乌司奴单抗暴露组更可能患有克罗恩病。
  • 乌司奴单抗暴露队列早产率0.0%,低于维多珠单抗(13.8%)、抗TNF(8.2%)、联合治疗(14.2%)、免疫调节剂(12.3%)及无暴露(9.7%)队列(P=0.03)。
  • 宫内暴露于维多珠单抗或乌司奴单抗未增加自发流产、小于胎龄儿、低出生体重、新生儿重症监护住院、先天畸形或宫内生长受限风险。
  • 出生时、4个月及生后12个月内严重感染率在所有队列间相当。
  • 乌司奴单抗暴露妊娠在12个月时非严重感染较低;维多珠单抗队列未发现胎盘并发症风险信号。

关键数值与推荐

  • 乌司奴单抗暴露组早产率0.0%,维多珠单抗组13.8%,抗TNF组8.2%,联合治疗组14.2%,免疫调节剂组12.3%,无暴露组9.7%(P=0.03)。

临床怎么用

  • 讨论部分推荐妊娠期继续使用乌司奴单抗和维多珠单抗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnancy outcomes in patients with inflammatory bowel disease with quiescent disease are similar to those in the general population. Data from the Pregnancy Inflammatory bowel disease And Neonatal Outcomes registry have demonstrated the safety of antitumor necrosis factor (TNF) α agents and thiopurines in pregnancy. The objective of this study was to provide information from the Pregnancy Inflammatory bowel disease And Neonatal Outcomes registry on maternal and fetal outcomes in patients exposed to the newer biologics ustekinumab (UST) and vedolizumab (VDZ). METHODS: In this multicenter prospective observational study, we included pregnant women with singleton pregnancies and a diagnosis of inflammatory bowel disease. Questionnaires were administered to women at study intake, each subsequent trimester, delivery, and 4, 9, and 12 months after birth. Bivariate analyses were used to determine the independent effects of specific drug classes on outcomes. The exposure cohorts were VDZ, UST, anti-TNF, immunomodulators, and combination with anti-TNF and immunomodulators. All were compared with no exposure and with biologics/immunomodulators. RESULTS: There were 1,669 completed pregnancies with 1,610 live births. The maternal mean age was 32.1 (SD 4.6) years at delivery with 66 VDZ exposed and 47 UST exposed. Women on UST were more likely to have Crohn's disease. There was no increased risk of spontaneous abortion, small for gestational age, low birth weight, neonatal intensive care unit stay, congenital malformations, or intrauterine growth restriction with in utero VDZ or UST exposure. The rate of preterm birth was lower (0.0%) for the UST-exposed cohort when compared with other cohorts including VDZ (13.8%), anti-TNF (8.2%), combination therapy (14.2%), immunomodulators (12.3%), and unexposed (9.7%) ( P = 0.03). Rates of serious infections at birth, 4 months, and within the first 12 months of life were comparable among all cohorts. Nonserious infections were lower at 12 months in UST-exposed pregnancies. There was no increased risk signal for placental complications in the VDZ cohort. UST infant concentrations at birth were increased whereas VDZ concentrations were overall decreased compared with maternal serum drug concentration. DISCUSSION: This analysis of UST and VDZ exposure during pregnancy suggests no increase in complications compared with TNF, immunomodulators, and combination TNF/immunomodulators. No signal was found for increased placental events with either therapy. Continuation of UST and VDZ throughout pregnancy is recommended.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Chugh R, Long MD, Jiang Y, et al. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry. Am J Gastroenterol. 2023. PMID: 37796648. doi:10.14309/ajg.0000000000002553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。